CL2008000197A1 - Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer. - Google Patents

Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.

Info

Publication number: CL2008000197A1
Authority: CL; Chile
Prior art keywords: compounds; antranilamide; pirimidina; cinasa; aurora
Prior art date: 2007-01-26

Application number

CL200800197A

Other languages

English (en)

Inventor

Jeffrey Michael Axten

Deborah L Bryan

David Harold Drewry

Thomas H Faitg

Timothy Francis Gallagher

Neil W Johnson

Jiri Kasparec

Jeffrey M Ralph

Domingos J Silva

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-01-26

Filing date

2008-01-24

Publication date

2008-08-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39644890&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008000197(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-01-24 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

2008-08-01 Publication of CL2008000197A1 publication Critical patent/CL2008000197A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

CL200800197A 2007-01-26 2008-01-24 Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer. CL2008000197A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US88667607P	2007-01-26	2007-01-26

Publications (1)

Publication Number	Publication Date
CL2008000197A1 true CL2008000197A1 (es)	2008-08-01

Family

ID=39644890

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200800197A CL2008000197A1 (es)	2007-01-26	2008-01-24	Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.

Country Status (10)

Country	Link
US (2)	US7884098B2 (es)
EP (1)	EP2121637A4 (es)
JP (1)	JP5337712B2 (es)
AR (1)	AR065015A1 (es)
AU (1)	AU2008207809B2 (es)
CA (1)	CA2676257A1 (es)
CL (1)	CL2008000197A1 (es)
PE (1)	PE20081636A1 (es)
TW (1)	TW200902010A (es)
WO (1)	WO2008092049A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2004265288A1 (en)	2003-07-30	2005-02-24	Rigel Pharmaceuticals, Inc.	2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
AR065015A1 (es) *	2007-01-26	2009-05-13	Smithkline Beecham Corp	Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer
WO2008118823A2 (en) *	2007-03-26	2008-10-02	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
WO2009127642A2 (en) *	2008-04-15	2009-10-22	Cellzome Limited	Use of lrrk2 inhibitors for neurodegenerative diseases
EA029131B1 (ru)	2008-05-21	2018-02-28	Ариад Фармасьютикалз, Инк.	Фосфорсодержащие производные в качестве ингибиторов киназы
US9273077B2 (en)	2008-05-21	2016-03-01	Ariad Pharmaceuticals, Inc.	Phosphorus derivatives as kinase inhibitors
US11351168B1 (en)	2008-06-27	2022-06-07	Celgene Car Llc	2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en)	2008-06-27	2012-12-25	Celgene Avilomics Research, Inc.	2,4-disubstituted pyrimidines useful as kinase inhibitors
RU2536584C2 (ru) *	2008-06-27	2014-12-27	Авила Терапьютикс, Инк.	Гетероарильные соединения и их применение
EP2440559B1 (en)	2009-05-05	2018-01-10	Dana-Farber Cancer Institute, Inc.	Egfr inhibitors and methods of treating disorders
CN101585781B (zh) *	2009-07-08	2012-08-08	北京颖新泰康国际贸易有限公司	一种邻氨基-n,n-二甲基苯甲酰胺的制备方法
US8933227B2 (en)	2009-08-14	2015-01-13	Boehringer Ingelheim International Gmbh	Selective synthesis of functionalized pyrimidines
US8729265B2 (en)	2009-08-14	2014-05-20	Boehringer Ingelheim International Gmbh	Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
SG187796A1 (en)	2010-08-10	2013-03-28	Celgene Avilomics Res Inc	Besylate salt of a btk inhibitor
CN101973956B (zh) *	2010-09-26	2013-07-31	合肥星宇化学有限责任公司	靛红酸酐的合成方法及n-异丙基-2-氨基苯甲酰胺的合成方法
WO2012061303A1 (en)	2010-11-01	2012-05-10	Avila Therapeutics, Inc.	Heteroaryl compounds and uses thereof
WO2012061299A1 (en)	2010-11-01	2012-05-10	Avila Therapeutics, Inc.	Heterocyclic compounds and uses thereof
WO2012064706A1 (en)	2010-11-10	2012-05-18	Avila Therapeutics, Inc.	Mutant-selective egfr inhibitors and uses thereof
CN102173999A (zh) *	2011-02-28	2011-09-07	盐城工学院	一种2-氨基-n,n-二甲基苯甲酰胺的合成方法
WO2012135641A2 (en)	2011-03-30	2012-10-04	H. Lee Moffitt Cancer Center And Research Institute	Aurora kinase inhibitors and methods of making and using thereof
BR112013025387B1 (pt)	2011-04-01	2021-07-27	University Of Utah Research Foundation	Compostos análogos substituídos da n-fenilpirimidin-2-amina como inibidores da quinase axl, uso dos ditos compostos para o tratamento de um distúrbio de proliferação celular descontrolada, bem como kit compreendendo ditos compostos
EA201391626A1 (ru)	2011-05-04	2014-03-31	Ариад Фармасьютикалз, Инк.	Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
TW201325593A (zh)	2011-10-28	2013-07-01	Celgene Avilomics Res Inc	治療布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶疾病或病症之方法
AU2012343325A1 (en) *	2011-11-21	2014-06-12	Cancer Therapeutics Crc Pty Ltd	Binding agent
US9056839B2 (en)	2012-03-15	2015-06-16	Celgene Avilomics Research, Inc.	Solid forms of an epidermal growth factor receptor kinase inhibitor
PT2825042T (pt)	2012-03-15	2018-11-16	Celgene Car Llc	Sais de um inibidor de cinases do recetor do fator de crescimento epidérmico
JP6469567B2 (ja)	2012-05-05	2019-02-13	アリアド・ファーマシューティカルズ・インコーポレイテッド	Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
GB201214106D0 (en) *	2012-08-07	2012-09-19	Univ Strathclyde	Immunomodulatory compounds
PH12015501130B1 (en)	2012-11-21	2023-01-27	Ptc Therapeutics Inc	Substituted reverse pyrimidine bmi-1 inhibitors
EP2935226A4 (en)	2012-12-21	2016-11-02	Celgene Avilomics Res Inc	HETEROARYL COMPOUNDS AND USES THEREOF
JP2016509012A (ja)	2013-02-08	2016-03-24	セルジーンアビロミクスリサーチ，インコーポレイテッド	Ｅｒｋ阻害剤およびそれらの使用
AU2014236820B2 (en)	2013-03-14	2018-08-02	Sumitomo Pharma Oncology, Inc.	JAK2 and ALK2 inhibitors and methods for their use
US9611283B1 (en)	2013-04-10	2017-04-04	Ariad Pharmaceuticals, Inc.	Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en)	2013-08-27	2016-11-15	Celgene Avilomics Research, Inc.	Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
WO2015030847A1 (en)	2013-08-30	2015-03-05	Ptc Therapeutics, Inc.	Substituted pyrimidine bmi-1 inhibitors
EP3071553A4 (en)	2013-11-21	2017-08-02	PTC Therapeutics, Inc.	Substituted pyridine and pyrazine bmi-1 inhibitors
US9415049B2 (en)	2013-12-20	2016-08-16	Celgene Avilomics Research, Inc.	Heteroaryl compounds and uses thereof
WO2016025561A1 (en)	2014-08-13	2016-02-18	Celgene Avilomics Research, Inc.	Forms and compositions of an erk inhibitor
CN105017160B (zh) *	2015-06-24	2017-12-29	温州医科大学	一种嘧啶类egfrt790m抑制剂及其合成方法和应用
CN106187914B (zh) *	2016-07-12	2019-03-15	黄河三角洲京博化工研究院有限公司	一种2,4-二氯-5-甲氧基嘧啶的制备方法
TW202411220A (zh) *	2016-12-19	2024-03-16	美商雅酶股份有限公司	作為ehmt2抑制劑之胺取代的雜環化合物及其使用方法
CA3060416A1 (en)	2017-04-21	2018-10-25	Epizyme, Inc.	Combination therapies with ehmt2 inhibitors
WO2019195753A1 (en)	2018-04-05	2019-10-10	Tolero Pharmaceuticals, Inc.	Axl kinase inhibitors and use of the same
US11442063B2 (en) *	2018-05-30	2022-09-13	Promega Corporation	Broad spectrum kinase binding agents
CN112512597A (zh)	2018-07-26	2021-03-16	大日本住友制药肿瘤公司	用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂
AU2019340402B2 (en)	2018-08-17	2025-04-03	Ptc Therapeutics, Inc.	Method for treating pancreatic cancer
CA3107743A1 (en)	2018-08-27	2020-03-05	Sumitomo Dainippon Pharma Co., Ltd.	Optically active azabicyclic derivative
WO2021113689A1 (en) *	2019-12-06	2021-06-10	Yale University	Spak/osr inhibitors and methods of using same
JP7677997B2 (ja) *	2020-05-22	2025-05-15	プロメガコーポレイション	キナーゼターゲットエンゲージメントの増強
CN113061117B (zh) *	2021-03-30	2023-02-10	长治学院	一种2-((5-氯-2-(4-吗啉甲基苯胺基)嘧啶-4-基)氨基)苯甲酰胺衍生物
CN116444488A (zh) *	2022-01-14	2023-07-18	上海立森印迹医药技术有限公司	一种嘧啶-2,4-二胺衍生物及其制备方法和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60017898T2 (de)	1999-06-09	2006-01-12	Yamanouchi Pharmaceutical Co., Ltd.	Neuartige heterocyclische carboxamidderivate
GB0004887D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
MXPA03010099A (es) *	2001-05-08	2004-03-10	Schering Ag	Amidas de antranilamida-piridina selectivas como inhibidores de vegfr-2 y vegfr-3.
DE60225709T2 (de)	2001-11-01	2009-05-07	Janssen Pharmaceutica N.V.	Aminobenzamidderivate als inhibitoren der glycogensynthasekinase-3-
GB0206215D0 (en)	2002-03-15	2002-05-01	Novartis Ag	Organic compounds
AU2003226126A1 (en) *	2002-03-28	2003-10-13	Arizona Chemical Company	Resinates from monomer fatty acids
ATE433447T1 (de) *	2003-02-20	2009-06-15	Smithkline Beecham Corp	Pyrimiidinverbindungen
GB0305929D0 (en)	2003-03-14	2003-04-23	Novartis Ag	Organic compounds
PT1660458E (pt)	2003-08-15	2012-04-27	Novartis Ag	2,4-pirimidinodiaminas úteis no tratamento de doenças neoplásicas, desordens inflamatórias e do sistema imunitário
GB0321710D0 (en)	2003-09-16	2003-10-15	Novartis Ag	Organic compounds
MXPA06003054A (es) *	2003-09-18	2006-05-31	Novartis Ag	2,4-di-(fenil-amino)-pirimidinas utiles en el tratamiento de trastornos proliferativos.
EP1751136B1 (en)	2004-05-07	2014-07-02	Amgen Inc.	Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
EP1598343A1 (de)	2004-05-19	2005-11-23	Boehringer Ingelheim International GmbH	2-Arylaminopyrimidine als PLK Inhibitoren
GB0419161D0 (en)	2004-08-27	2004-09-29	Novartis Ag	Organic compounds
JP2009525337A (ja)	2006-01-30	2009-07-09	エクセリクシス，インク．	Ｊａｋ−２調節因子としての４−アリール−２−アミノ−ピリミジン類又は４−アリール−２−アミノアルキル−ピリミジン類と使用方法
CN103641833A (zh)	2006-12-08	2014-03-19	Irm责任有限公司	作为蛋白激酶抑制剂的化合物和组合物
EP2099771A1 (en) *	2006-12-19	2009-09-16	Genentech, Inc.	Pyrimidine kinase inhibitors
AR065015A1 (es) *	2007-01-26	2009-05-13	Smithkline Beecham Corp	Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer
EA200901138A1 (ru) *	2007-03-20	2010-04-30	Смитклайн Бичем Корпорейшн	Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение

2008
- 2008-01-24 AR ARP080100292A patent/AR065015A1/es unknown
- 2008-01-24 CL CL200800197A patent/CL2008000197A1/es unknown
- 2008-01-24 PE PE2008000182A patent/PE20081636A1/es not_active Application Discontinuation
- 2008-01-24 TW TW097102587A patent/TW200902010A/zh unknown
- 2008-01-25 US US12/524,009 patent/US7884098B2/en not_active Expired - Fee Related
- 2008-01-25 WO PCT/US2008/051985 patent/WO2008092049A1/en not_active Ceased
- 2008-01-25 JP JP2009547435A patent/JP5337712B2/ja not_active Expired - Fee Related
- 2008-01-25 US US12/019,730 patent/US7625903B2/en not_active Expired - Fee Related
- 2008-01-25 EP EP08728247A patent/EP2121637A4/en not_active Withdrawn
- 2008-01-25 AU AU2008207809A patent/AU2008207809B2/en not_active Ceased
- 2008-01-25 CA CA002676257A patent/CA2676257A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP2121637A1 (en)	2009-11-25
AR065015A1 (es)	2009-05-13
AU2008207809B2 (en)	2013-04-18
US20100016318A1 (en)	2010-01-21
US7884098B2 (en)	2011-02-08
CA2676257A1 (en)	2008-07-31
JP5337712B2 (ja)	2013-11-06
AU2008207809A1 (en)	2008-07-31
US7625903B2 (en)	2009-12-01
WO2008092049A1 (en)	2008-07-31
JP2010516780A (ja)	2010-05-20
TW200902010A (en)	2009-01-16
US20080182852A1 (en)	2008-07-31
PE20081636A1 (es)	2009-01-10
EP2121637A4 (en)	2010-10-06

Similar Documents

Publication	Publication Date	Title
CL2008000197A1 (es)	2008-08-01	Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CL2007003226A1 (es)	2008-02-08	Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
CL2008002319A1 (es)	2009-01-02	Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CL2008000754A1 (es)	2008-10-24	Compuesto derivado de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso para tratar cancer y trastornos hiperproliferativos.
CL2008000029A1 (es)	2008-04-04	Compuestos derivados de 1-bencil imidazol, inhibidores de eg-5; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CL2007003212A1 (es)	2008-06-27	Compuestos derivados de imidazopirazinas, inhibidores de proteina quinasa; composicion farmaceutica que los comprende; y su uso para tratar cancer.
CL2007003138A1 (es)	2008-06-27	Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2008000793A1 (es)	2008-05-30	Compuestos derivados de dihidroindazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno del hierro.
CL2008000794A1 (es)	2008-05-30	Compuestos derivados de biarilo y heteroarilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno de hierro.
CL2008000094A1 (es)	2008-05-23	Compuestos derivados de pteridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para aumentar la vasodilatacion.
CL2007003244A1 (es)	2008-04-04	Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2007003202A1 (es)	2008-03-07	Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular.
CL2008000703A1 (es)	2008-09-26	Compuestos derivados de pirimidinas sustituidas; procedimiento para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar transtornos hematologicos.
CL2007002578A1 (es)	2008-07-04	Compuestos derivados de n-(1-ftalazin-1-il-piperidin-4-il)-amidas; composicion farmaceutica; y uso para el tratamiento y prevencion de trastornos de la fertilidad, osteoporosis y cancer.
CL2007002916A1 (es)	2008-04-18	Compuestos derivados de pirazoliltienopiridinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en la inhibicion de escaras.
CL2007002234A1 (es)	2008-06-13	Compuestos derivados de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.
CL2007001995A1 (es)	2008-01-25	Compuestos derivados de pirrolotriazina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el cancer.
CL2007002107A1 (es)	2008-06-06	Compuestos derivados de bencil piperidin-1-il amina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hiperlipidemia, arterioesclerosis, ateroesclerosis, vasculopatia periferica, dislipidemia, entre otras enfermedades.
CL2007002021A1 (es)	2008-02-08	Compuestos derivados de oxoisoindol; composicion farmaceutica que los comprende; y su uso para tratar arritmias.
CL2008002295A1 (es)	2009-03-27	Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
BRPI0814593A2 (pt)	2015-01-20	Composto, composição farmacêutica que o contém e uso do composto.
CL2007003108A1 (es)	2008-07-18	Compuestos derivados de n-hidroxiamida sustituida con heterociclos, inhibidores de histona desacetilasa; composicion farmaceutica que comprende a dichos compuestos; y uso para tratar una enfermedad del grupo que consiste en enfermedad de huntington,
CL2008000046A1 (es)	2008-05-09	Compuestos derivados de 2-(4-piperidin-3-il-fenil)-7-amido-2,7a-dihidro-1h-indazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar o prevenir el cancer, enfermedades inflamatorias, lesiones por reperfusion, afeccione
CL2008001323A1 (es)	2009-05-29	Compuestos derivados de triazolil aminopiridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CL2007001325A1 (es)	2008-07-18	Compuestos derivados de biciclos, inhibidores de cept; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hiperlipidemia, arterioesclerosis, entre otras enfermedades.